NetraMark Delivers Transformational Quarter Of Execution

Executive Summary

• Contract backlog grew to approximately C$2.5 million, supporting the company’s guidance of reaching C$8‑10 million by mid‑2026.
• Completed onboarding with Worldwide Clinical Trials, enabling NetraMark to compete for Phase 2/3 CNS and Oncology bids worldwide.
• Achieved key regulatory engagement (FDA Critical Path Innovation Meeting) and scientific validation (npj Digital Medicine publication, CAMH research award).

Key Details

• Contract Backlog: Increased to ~C$2.5 M in the quarter; target C$8‑10 M by mid‑2026.
• Channel Partner: Master services agreement with Worldwide Clinical Trials executed 3 Apr 2025; onboarding completed Oct 2025, granting access to Worldwide’s Phase 2/3 bids for CNS and Oncology programs.
• FDA CPIM (Dec 2025): Non‑binding scientific exchange; FDA provided feedback on NetraAI’s enrichment methodology, discussed Type I error control, and suggested exploring the MIDD Paired Meeting Program. No endorsement was given.
• Nature Portfolio Publication: Study of NetraAI accepted in npj Digital Medicine (8 Dec 2025); co‑authored with NIMH researchers; demonstrated improved patient stratification in a Phase II depression trial.
• CAMH Collaboration: Awarded Ontario Research Fund – Research Excellence (ORF‑RE) award; NetraAI deployed in CAMH’s secure environment to analyze genetic/epigenetic data for schizophrenia and major depressive disorder, aiming to identify explainable subpopulations.
• Outlook: Reiterated guidance of C$8‑10 M booked contract backlog by mid‑2026; expects continued commercial momentum from direct client engagements, expanded channel partnerships, and an active pipeline of late‑stage opportunities.

Notable Quotes

“This quarter reflects disciplined execution across key areas of our business… Growing commercial traction, constructive scientific engagement with the FDA, and increasing third‑party validation reinforce that our approach is both novel and increasingly aligned with modern clinical development.” – George Achilleos, CEO

Materiality: Material – Positive (the release provides substantive updates on revenue‑related backlog growth, strategic partnerships, regulatory feedback, and scientific validation that are likely to influence investor perception.)